|
IFNβ-1a 44 mcg three times weekly (n = 48)
|
IFNβ-1a 22 mcg three times weekly (n = 53)
|
---|
Age (years)
|
34.2 ± 8.4
|
35.3 ± 8.2
|
Sex (fem/male)
|
30 (62.5%)/18 (37.5%)
|
41 (77.4%)/12 (22.6%)
|
Age at disease onset
|
29.2 ± 8.3
|
30.4 ± 8.1
|
Duration of MS (years)
|
5.2 ± 4.3
|
4.9 ± 4.2
|
EDSS score
|
1.7 ± 1.0
|
1.6 ± 1.0
|
Annual relapse rate prior to therapy
|
0.8 ± 0.9
|
1.0 ± 1.2
|
- Data are expressed as means, except for sex (expressed in number and percentage); EDSS: Expanded Disability Status Scale; IFNβ-1a: interferon beta 1a; MS: multiple sclerosis. All p values for comparisons of the characteristics listed above, between the two treatment groups, were not significant.